Journal
AIDS
Volume 32, Issue 11, Pages 1541-1543Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QAD.0000000000001859
Keywords
-
Categories
Funding
- National Institutes of Health [K23 MH099916, P30 AI060354]
- Alexander von Humboldt Foundation through the Alexander von Humboldt Professor award
- Federal Ministry of Education and Research
- Wellcome Trust
- European Commission
- NICHD of NIH [R01-HD084233]
- NIA of NIH [P01-AG041710]
- NIAID of NIH [R01-AI124389, R01-AI112339]
- FIC of NIH [D43-TW009775]
- Olympia-Morata programme of the University of Heidelberg, Germany
- Heidelberg Institute of Public Health, Germany
Ask authors/readers for more resources
Long-acting injectable (LAI) HIV pre-exposure prophylaxis (PrEP) may mitigate adherence challenges reported by young women in Southern Africa. We assessed preferences for PrEP in public-sector, primary care clinics in Swaziland. Among surveyed respondents, 75% (95% confidence interval = 65-83%) stated preference for LAI over oral PrEP; with no differences by sex, age, or sexual behavior (all P>0.05). Notably, over 70% (95% confidence interval 58-82%) with current use of oral PrEP also stated preference for LAI PrEP.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
